9.91

0.10% -0.010

Exozymes Inc (EXOZ)

Overview News Price History Discussions Forecast

Exozymes Inc stock is traded at $9.91, with a volume of 1,232. It is down -0.10% in the last 24 hours and down -3.88% over the past month. EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.

Previous Close:

$9.92

Open:

$10.43

24h Volume:

1,232

Relative Volume:

0.27

Market Cap:

$84.03M

Revenue:

$70,100

Net Income/Loss:

$-9.67M

P/E Ratio:

-8.6092

EPS:

-1.1511

Net Cash Flow:

$-7.09M

1W Performance:

+4.32%

1M Performance:

-3.88%

6M Performance:

-35.27%

1Y Performance:

-33.49%

1-Day Range:

$9.91

$10.43

1-Week Range:

$9.2001

$11.30

52-Week Range:

$7.08

$18.40

Exozymes Inc Stock (EXOZ) Company Profile

Name

Exozymes Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(626) - 415 - 1488

Address

750 ROYAL OAKS DR, MONROVIA

Employee

Twitter

Next Earnings Date

2026-05-18

Latest SEC Filings

EXOZ's Discussions on Twitter

Compare EXOZ vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXOZ Exozymes Inc	9.91	84.11M	70,100	-9.67M	-7.09M	-1.1511
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Exozymes Inc Stock (EXOZ) Latest News

May 22, 2026

Number of shareholders of eXoZymes Inc. – NASDAQ:EXOZ - TradingView

May 22, 2026

May 20, 2026

EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill

May 20, 2026

May 14, 2026

EXOZYMES INC. 1Q 2026: Revenue $0 Net income $(2.37M) — 10-Q Summary - TradingView

May 14, 2026

EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

eXoZymes (NASDAQ: EXOZ) Q1 2026 loss deepens amid cash burn, planned raise - Stock Titan

May 14, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 07, 2026

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - ACCESS Newswire

May 07, 2026

eXoZymes Prepares Investor Presentation for Proposed Public Offering - TipRanks

May 07, 2026

eXoZymes (EXOZ) files investor presentation for proposed securities offering - Stock Titan

May 07, 2026

Apr 26, 2026

Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review

Apr 26, 2026

Apr 24, 2026

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review

Apr 24, 2026

eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat

Apr 24, 2026

Apr 18, 2026

Damien Alan Perriman Net Worth (2026) - GuruFocus

Apr 18, 2026

Apr 11, 2026

eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail

Apr 11, 2026

Apr 10, 2026

Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus

Apr 10, 2026

eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan

Apr 10, 2026

eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia

Apr 10, 2026

Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan

Apr 10, 2026

eXoZymes CCO discusses NCTx spinout on podcast - Investing.com

Apr 10, 2026

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire

Apr 10, 2026

Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan

Apr 10, 2026

Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Exozymes Incannounces common stock offeringSEC filing - marketscreener.com

Apr 09, 2026

eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan

Apr 09, 2026

Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan

Apr 08, 2026

EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan

Apr 08, 2026

Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 08, 2026

Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn

Apr 06, 2026

Apr 04, 2026

EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI

Apr 04, 2026

Apr 02, 2026

Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn

Apr 02, 2026

Apr 01, 2026